Asthma Clinical Trial
— SIPOfficial title:
The SIP Study: Simultaneously Implementing Pathways for Improving Asthma, Pneumonia, and Bronchiolitis Care for Hospitalized Children
This study's objective is to identify and test pragmatic and sustainable strategies for implementing a multi-condition clinical pathway intervention for children hospitalized with asthma, pneumonia, or bronchiolitis in community hospitals. The hypothesis is that the multi-condition pathway intervention will be associated with significantly greater increases in clinicians' adoption of evidence-based practices compared to control. The study is a pragmatic, cluster-randomized trial in US community hospitals. The primary outcome will be adoption of evidence-based practices over a sustained period of 2 years. Secondary outcomes include length of hospital stay, intensive care unit transfer, and hospital readmission/emergency department revisit.
Status | Recruiting |
Enrollment | 16800 |
Est. completion date | June 30, 2026 |
Est. primary completion date | September 30, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A to 17 Years |
Eligibility | Inclusion Criteria: - Primary diagnosis of asthma AND age >2 to <18 years-old at time of admission to the hospital OR - Primary diagnosis of pneumonia AND age >2 months and <18 years at time of admission to the hospital OR - Primary diagnosis of bronchiolitis AND age <2 years at time of admission to the hospital Exclusion Criteria: - Diagnosis of SARS-CoV-2 - Transfer in from another inpatient facility - Pre-existing chronic illnesses (e.g., lung disease, cardiovascular disease, neurologic disorders) |
Country | Name | City | State |
---|---|---|---|
United States | University of California, San Francisco | San Francisco | California |
Lead Sponsor | Collaborator |
---|---|
University of California, San Francisco | National Heart, Lung, and Blood Institute (NHLBI), Society of Hospital Medicine |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Pneumonia Evidence Based Practice 1 | Administration of narrow spectrum antibiotic | During a hospitalization, approximately 2 days | |
Primary | Pneumonia Evidence Based Practice 2 | No prescription of macrolide antibiotics | During a hospitalization, approximately 2 days | |
Primary | Asthma Evidence Based Practice 1 | Prescription of inhaled corticosteroids for children greater than or equal to 5 years-old | During a hospitalization, approximately 2 days | |
Primary | Asthma Evidence Based Practice 2 | Use of metered-dose inhalers | During a hospitalization, approximately 2 days | |
Primary | Asthma Evidence Based Practice 3 | Use of an asthma pathway/bronchodilator weaning protocol | During a hospitalization, approximately 2 days | |
Primary | Bronchiolitis Evidence Based Practice 1 | No administration of bronchodilators | During a hospitalization, approximately 2 days | |
Primary | Bronchiolitis Evidence Based Practice 2 | No chest radiographs | During a hospitalization, approximately 2 days | |
Secondary | Length of Hospital Stay | Length Hospital Stay | During a hospitalization, approximately 2 days | |
Secondary | Transfer to Intensive Care | The event of patient being transferred to an ICU | During a hospitalization, approximately 2 days | |
Secondary | 30-day Hospital Readmission or Emergency Department Revisit | Event of a patient being readmitted to hospital or having an emergency department visit within 30 days of hospital discharge | 30 days after hospital discharge |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|